AUB ScholarWorks

Biphasic insulin aspart 30 treatment in patients with type 2 diabetes poorly controlled on prior diabetes treatment: Results from the PRESENT study

Show simple item record Sharma S.K. Al-Mustafa M. Oh S.J. Azar S.T. Shestakova M. Guler S. Vaz J.A.
dc.contributor.editor Mar-2008 2017-10-05T15:37:28Z 2017-10-05T15:37:28Z 2008
dc.identifier 10.1185/030079908X260952
dc.identifier.issn 03007995
dc.description.abstract Aim: The safety and efficacy of biphasic insulin aspart (BIAsp30) were evaluated in patients uncontrolled on previous treatment (human insulin ± oral hypoglycaemic agent [OHA] or OHA only) in routine clinical practice. Methods: This was a large, multi-national, multicentre, prospective, 6-month study in type 2 diabetes mellitus patients who were prescribed BIAsp30. Changes in glycated haemoglobin (HbA1c), fasting plasma glucose (FPG), postprandial plasma glucose (PPPG), proportion who achieved target HbA 1c andlt; 7percent and rate of hypoglycaemic episodes were assessed. This paper evaluates outcomes in patients by diabetes duration (andlt; 5, 5-10, 10-20 or ≥ 20 years) stratified by prior therapy. Results: After 6 months of treatment, glycaemia improved significantly across the duration subgroups. The improvement was better in insulin-naïve group versus prior insulin group: HbA1c decreased ∼ 2.2percent-points versus ∼ 1.6percent-points, FPG decreased ∼ 4.5 mmol-L versus ∼ 2.9 mmol-L and PPPG decreased ∼ 6.8 mmol-L versus ∼ 5.0 mmol-L. Target HbA1c was achieved by about one in four patients although insulin-naïve patients achieved this at comparatively lower BIAsp30 dose. Body weight remained relatively unchanged. Hypoglycaemic episodes appeared to be more frequent in the prior insulin group which decreased during the treatment period. Conclusions: According to this observational study, in clinical practice, initiating or transferring uncontrolled patients to biphasic insulin aspart improved glycaemic control without using a strict insulin algorithm. © 2008 Librapharm Limited All rights reserved.
dc.format.extent Pages: (645-652)
dc.language English
dc.publisher LONDON
dc.relation.ispartof Publication Name: Current Medical Research and Opinion; Publication Year: 2008; Volume: 24; no. 3; Pages: (645-652);
dc.source Scopus
dc.title Biphasic insulin aspart 30 treatment in patients with type 2 diabetes poorly controlled on prior diabetes treatment: Results from the PRESENT study
dc.type Article
dc.contributor.affiliation Sharma, S.K., M.G. Medical College, Jaipur, India, 11, Shivaji Nagar, Civil Lines, Jaipur, 302006, India
dc.contributor.affiliation Al-Mustafa, M., National Diabetes Centre, Baghdad, Iraq
dc.contributor.affiliation Oh, S.J., Kyung Hee University Hospital, South Korea
dc.contributor.affiliation Azar, S.T., American University of Beirut, Beirut, Lebanon
dc.contributor.affiliation Shestakova, M., Institute of Diabetes, Moscow, Russian Federation
dc.contributor.affiliation Guler, S., Ankara Numune Training and Research Hospital, Ankara, Turkey
dc.contributor.affiliation Vaz, J.A., Novo Nordisk International Operations Clinical Development Centre, Singapore, Singapore
dc.contributor.authorAddress Sharma, S. K.11, Shivaji Nagar, Civil Lines, Jaipur, 302006, India; email:
dc.contributor.authorCorporate University: American University of Beirut Medical Center; Faculty: Faculty of Medicine; Department: Internal Medicine;
dc.contributor.authorDepartment Internal Medicine
dc.contributor.faculty Faculty of Medicine
dc.contributor.authorInitials Sharma, SK
dc.contributor.authorInitials Al-Mustafa, M
dc.contributor.authorInitials Oh, SJ
dc.contributor.authorInitials Azar, ST
dc.contributor.authorInitials Shestakova, M
dc.contributor.authorInitials Guler, S
dc.contributor.authorInitials Vaz, JA
dc.contributor.authorReprintAddress Sharma, SK (reprint author), 11 Shivaji Nagar,Civil Lines, Jaipur 302006, Rajasthan, India.
dc.contributor.authorUniversity American University of Beirut Medical Center
dc.description.cited AACE Diabetes Mellitus Clinical Practice Guidelines Task Force, 2007, ENDOCR PRACT S1, V13, P3; Abrahamian H, 2005, HORM METAB RES, V37, P684, DOI 10.1055-s-870579; Bell DSH, 2006, DIABETES OBES METAB, V8, P110, DOI 10.1111-j.1463-1326.2005.00560.x; DAVIDSON J, 2005, CLIN THER, V27, P75; de Sonnaville JJJ, 1998, DIABETES CARE, V21, P919, DOI 10.2337-diacare.21.6.919; DICKSON PJ, 2002, PRCT DIAB INT, V19, P67, DOI 10.1002-pdi.331; Garber AJ, 2006, DIABETES OBES METAB, V8, P58, DOI 10.1111-j.1463-1326.2005.00563.x; HALIMI S, 2005, CLIN THER, V27, P57; IDF Clinical Guidelines Task Force, 2005, GLOB GUID TYP 2 DIAB; Kilo C, 2003, J DIABETES COMPLICAT, V17, P307, DOI 10.1016-S1056-8727(03)00076-X; Kvapil M, 2006, Diabetes Obes Metab, V8, P39, DOI 10.1111-j.1463-1326.2005.00492.x; Mayfield JA, 2004, AM FAM PHYSICIAN, V70, P2079; Nathan DM, 2006, DIABETES CARE, V29, P1963, DOI 10.2337-dc06-9912; Raccah D, 2007, DIABETES-METAB RES, V23, P257, DOI 10.1002-dmrr.733; Raccah D, 2006, DIABETES METAB, V32, P244, DOI 10.1016-S1262-3636(07)70275-6; Raskin P, 2005, DIABETES CARE, V28, P260, DOI 10.2337-diacare.28.2.260; Raz I, 2003, CLIN THER, V25, P3109, DOI 10.1016-S0149-2918(03)90095-6; Schwartz S, 2003, DIABETES CARE, V26, P2238, DOI 10.2337-diacare.26.8.2238; SHESTAKOVA M, 2007, TRANSFERRING TYPE 2; Skovlund S. E., 2005, DIABETES SPECTRUM, V18, P136, DOI DOI 10.2337-DIASPECT.18.3.136; Stratton IM, 2000, BRIT MED J, V321, P405, DOI 10.1136-bmj.321.7258.405; The DCCT Research Group, 1995, DIABETES, V44, P968, DOI DOI 10.2337-DIABETES.44.8.968; Turner RC, 1999, JAMA-J AM MED ASSOC, V281, P2005, DOI 10.1001-jama.281.21.2005; Wright A, 2002, DIABETES CARE, V25, P330, DOI 10.2337-diacare.25.2.330
dc.description.citedCount 22
dc.description.citedTotWOSCount 13
dc.description.citedWOSCount 13
dc.format.extentCount 8
dc.identifier.coden CMROC
dc.identifier.pubmedID 18215338
dc.identifier.scopusID 41149143684
dc.relation.ispartOfISOAbbr Curr. Med. Res. Opin.
dc.relation.ispartOfIssue 3
dc.relation.ispartofPubTitle Current Medical Research and Opinion
dc.relation.ispartofPubTitleAbbr Curr. Med. Res. Opin.
dc.relation.ispartOfVolume 24
dc.source.ID WOS:000254393800004
dc.type.publication Journal
dc.subject.otherAuthKeyword Biphasic insulin aspart 30
dc.subject.otherAuthKeyword HbA1c
dc.subject.otherAuthKeyword Human insulin
dc.subject.otherAuthKeyword Hypoglycaemia
dc.subject.otherAuthKeyword Oral hypoglycaemic agents
dc.subject.otherAuthKeyword Type 2 diabetes mellitus
dc.subject.otherChemCAS glucose, 50-99-7, 84778-64-3
dc.subject.otherChemCAS hemoglobin A1c, 62572-11-6
dc.subject.otherChemCAS insulin, 9004-10-8
dc.subject.otherChemCAS Blood Glucose
dc.subject.otherChemCAS Hemoglobin A, Glycosylated
dc.subject.otherChemCAS Hypoglycemic Agents
dc.subject.otherChemCAS Insulin, 11061-68-0
dc.subject.otherChemCAS insulin, Asp(B28)-
dc.subject.otherIndex biphasic insulin aspart 30
dc.subject.otherIndex glucose
dc.subject.otherIndex hemoglobin A1c
dc.subject.otherIndex insulin
dc.subject.otherIndex insulin derivative
dc.subject.otherIndex oral antidiabetic agent
dc.subject.otherIndex unclassified drug
dc.subject.otherIndex adult
dc.subject.otherIndex article
dc.subject.otherIndex body weight
dc.subject.otherIndex clinical practice
dc.subject.otherIndex clinical trial
dc.subject.otherIndex controlled clinical trial
dc.subject.otherIndex controlled study
dc.subject.otherIndex diabetes control
dc.subject.otherIndex diet restriction
dc.subject.otherIndex disease duration
dc.subject.otherIndex drug dose increase
dc.subject.otherIndex drug efficacy
dc.subject.otherIndex drug safety
dc.subject.otherIndex drug screening
dc.subject.otherIndex drug substitution
dc.subject.otherIndex female
dc.subject.otherIndex glucose blood level
dc.subject.otherIndex human
dc.subject.otherIndex hypoglycemia
dc.subject.otherIndex insulin treatment
dc.subject.otherIndex low drug dose
dc.subject.otherIndex male
dc.subject.otherIndex multicenter study
dc.subject.otherIndex non insulin dependent diabetes mellitus
dc.subject.otherIndex observational study
dc.subject.otherIndex outcome assessment
dc.subject.otherIndex prescription
dc.subject.otherIndex prospective study
dc.subject.otherIndex treatment duration
dc.subject.otherIndex treatment outcome
dc.subject.otherIndex Aged
dc.subject.otherIndex Blood Glucose
dc.subject.otherIndex Diabetes Mellitus, Type 2
dc.subject.otherIndex Female
dc.subject.otherIndex Glycemic Index
dc.subject.otherIndex Hemoglobin A, Glycosylated
dc.subject.otherIndex Humans
dc.subject.otherIndex Hypoglycemic Agents
dc.subject.otherIndex Insulin
dc.subject.otherIndex Male
dc.subject.otherIndex Middle Aged
dc.subject.otherIndex Postprandial Period
dc.subject.otherIndex Prospective Studies
dc.subject.otherIndex Treatment Failure
dc.subject.otherKeywordPlus THERAPY
dc.subject.otherKeywordPlus METFORMIN
dc.subject.otherKeywordPlus MELLITUS
dc.subject.otherKeywordPlus EFFICACY
dc.subject.otherKeywordPlus SULFONYLUREA
dc.subject.otherKeywordPlus ASSOCIATION
dc.subject.otherKeywordPlus INITIATION
dc.subject.otherWOS Medicine, General and Internal
dc.subject.otherWOS Medicine, Research and Experimental

Files in this item

Files Size Format View

There are no files associated with this item.

This item appears in the following Collection(s)

Show simple item record

Search AUB ScholarWorks


My Account